- Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
- Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
- Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
- Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
Revance Therapeutics Inc (RVNC:NMQ) closed at 22.23, -25.90% below its 52-week high of 30.00, set on Sep 27, 2021.
11.27Jun 14 202230.00Sep 27 2021
Markit short selling activity
|Market cap||1.57bn USD|
|EPS (TTM)||-3.84 |
Data delayed at least 15 minutes, as of Aug 18 2022 21:00 BST.